CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

48.92 -0.47 (-0.94%)

Delayed Quote Updated: 1:18 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

37 38 Next >

Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today? ↗

April 13, 2023

While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks.

Via InvestorPlace

CRISPR Therapeutics Is an Interesting 'Gene Editing Play for 2023' With Significant Upside, Says Analyst ↗

April 13, 2023

Via Benzinga

$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis ↗

April 13, 2023

Via Benzinga

Why Shares of CRISPR Therapeutics Jumped Thursday ↗

April 13, 2023

An independent drug-pricing group said that a $1.9 million cost for the company's exa-cel therapy would be cost-effective.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023 ↗

April 13, 2023

Via Benzinga

Where Will CRISPR Therapeutics Be in 5 Years? ↗

April 09, 2023

Could CRISPR Therapeutics be the next big healthcare stock?

Via The Motley Fool

Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 13, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

2 Nasdaq Growth Stocks That Are Screaming Buys in April ↗

April 13, 2023

Massive drivers of fresh earnings are drawing closer, and risks are declining.

Via The Motley Fool

These Up-and-Coming Stocks Are Screaming Buys Right Now ↗

April 13, 2023

Both companies could deliver revenue and share price growth over the long term.

Via The Motley Fool

Could This Move Make Vertex's Next Blockbuster Even Bigger? ↗

April 12, 2023

Vertex is showing it can branch out beyond its cystic fibrosis specialty.

Via The Motley Fool

Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity? ↗

April 10, 2023

The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.

Via Benzinga

CRISPR Stock: Bull vs. Bear ↗

April 08, 2023

CRISPR's first approved product may be right around the corner.

Via The Motley Fool

Why Bluebird Bio Shares Are Plunging Today ↗

March 29, 2023

Via Benzinga

5 S&P 500 Stocks Showing Strength As Recession Fears Rise ↗

April 07, 2023

Medical stocks are holding up amid economic and market uncertainty.

Via Investor's Business Daily

What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio ↗

April 06, 2023

Both biotechs are aiming for the same markets, but they are not equally risky.

Via The Motley Fool

Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio ↗

April 06, 2023

Neither stock is a good choice for those who can't handle a lot of risk.

Via The Motley Fool

Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global ↗

April 06, 2023

Via Benzinga

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

April 05, 2023

Both companies have game-changing product portfolios that should result in stock price growth.

Via The Motley Fool

Could This Stock Become the Tesla of Its Industry? ↗

March 25, 2023

It's in a race to a multi-billion dollar market.

Via The Motley Fool

Vertex Is 1 Step Closer to Bringing a New Blockbuster to Market. Time to Buy? ↗

April 04, 2023

Vertex shares are on the rise.

Via The Motley Fool

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

April 03, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

The 10 Best Stocks to Buy in April 2023 ↗

April 01, 2023

Here are 10 stocks to buy now that could unlock explosive gains in your growth-stock portfolio.

Via The Motley Fool

Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics ↗

April 01, 2023

Together, the companies could produce a game-changing product.

Via The Motley Fool

5 Bargain-Basement Stocks to Buy Right Now ↗

March 31, 2023

Down markets offer us something very positive: deals on quality companies.

Via The Motley Fool

The 3 Best Growth Stocks to Buy in the Biotech Sector ↗

March 29, 2023

These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors.

Via InvestorPlace

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗

March 29, 2023

For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.

Via InvestorPlace

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

March 27, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Could CRISPR Therapeutics Become the Next Moderna? ↗

March 27, 2023

Both companies use cutting-edge technology.

Via The Motley Fool

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket ↗

March 25, 2023

Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.

Via InvestorPlace

3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence ↗

March 24, 2023

Your stock screening and research process will never be the same.

Via The Motley Fool

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.